Trial Profile

Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Endometrial cancer; Uterine cancer
Focus Proof of concept; Therapeutic Use
Acronyms PAM

Most Recent Events

04 Jun 2024 Results assessing recurrence-free survival (RFS), and unique correlative clinicopathologic, genomic and immunologic biomarkers presented at the 60th Annual Meeting of the American Society of Clinical Oncology
04 Dec 2023 Status changed from recruiting to completed.
24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com